Ignite Creation Date:
2024-05-06 @ 3:04 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04510298
Status:
COMPLETED
Last Update Posted:
2022-04-25
First Post:
2020-07-27
Brief Title:
A Study of the Safety PK and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
Sponsor:
Sirtsei Pharmaceuticals Inc
Organization:
Sirtsei Pharmaceuticals Inc
Study Overview
Official Title:
A Pilot 4-Week Randomized Double-Blind Placebo-Controlled Inpatient Multicenter Study of the Safety Population Pharmacokinetics and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
Status:
COMPLETED
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None